We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+13.99%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$216M
AUM Growth
+$6.9M
Cap. Flow
-$12.7M
Cap. Flow %
-5.89%
Top 10 Hldgs %
39.36%
Holding
92
New
7
Increased
29
Reduced
20
Closed
8

Top Buys

Rank Stock Value
1
EVO icon
Evotec
EVO
+$1.42M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$1.3M
3
AMGN icon
Amgen
AMGN
+$1.04M
4
GDX icon
VanEck Gold Miners ETF
GDX
+$620K
5
GPCR icon
Structure Therapeutics
GPCR
+$544K

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$908K
2
XLE icon
State Street Energy Select Sector SPDR ETF
XLE
+$562K
3
XNCR icon
Xencor
XNCR
+$558K
4
ORCL icon
Oracle
ORCL
+$484K
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$462K

Sector Composition

Rank Sector Weight
1 Healthcare 30.72%
2 Technology 27.13%
3 Consumer Discretionary 7.96%
4 Communication Services 7.9%
5 Financials 4.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OI icon
51
O-I Glass
OI
$1.18B
$1.09M 0.51%
74,250
– –
ANAB icon
52
AnaptysBio
ANAB
$1.54B
$1.07M 0.49%
48,000
+13,150
+38% +$275K
SPOT icon
53
Spotify
SPOT
$107B
$959K 0.44%
1,250
– –
PRTA icon
54
Prothena Corp
PRTA
$448M
$950K 0.44%
156,500
-38,500
-20% -$289K
BP icon
55
BP
BP
$112B
$898K 0.42%
30,000
– –
STEW
56
SRH Total Return Fund
STEW
$1.77B
$884K 0.41%
50,000
– –
VRDN icon
57
Viridian Therapeutics
VRDN
$2.19B
$867K 0.4%
62,029
– –
PYPL icon
58
PayPal
PYPL
$50.3B
$818K 0.38%
11,000
– –
BHVN icon
59
Biohaven
BHVN
$2.01B
$797K 0.37%
56,500
+6,000
+12% +$107K
LRCX icon
60
Lam Research
LRCX
$315B
$730K 0.34%
7,500
– –
UBER icon
61
PUT
Uber
UBER
$145B
$700K 0.32%
+7,500
New +$617K
INTC icon
62
Intel
INTC
$415B
$672K 0.31%
30,000
-10,000
-25% -$207K
GDX icon
63
PUT
VanEck Gold Miners ETF
GDX
$22.6B
$651K 0.3%
+12,500
New +$620K
IWM icon
64
iShares Russell 2000 ETF
IWM
$79.1B
$647K 0.3%
3,000
– –
TPB icon
65
Turning Point Brands
TPB
$1.49B
$606K 0.28%
8,000
-2,100
-21% -$143K
ARQ icon
66
Arq
ARQ
$84.1M
$583K 0.27%
108,494
-4,939
-4% -$21.6K
TDOC icon
67
Teladoc Health
TDOC
$1.66B
$566K 0.26%
65,000
+12,500
+24% +$90.6K
GPCR icon
68
Structure Therapeutics
GPCR
$3.36B
$513K 0.24%
+24,750
New +$544K
ALT icon
69
CALL
Altimmune
ALT
$564M
$488K 0.23%
126,000
+31,000
+33% +$168K
LYFT icon
70
Lyft
LYFT
$5.87B
$473K 0.22%
30,000
-25,000
-45% -$350K
CTLP
71
DELISTED
Cantaloupe
CTLP
$368K 0.17%
33,500
+2,000
+6% +$17.3K
BUR icon
72
Burford Capital
BUR
$914M
$349K 0.16%
24,500
+3,500
+17% +$45.7K
MU icon
73
CALL
Micron Technology
MU
$842B
$308K 0.14%
2,500
-10,500
-81% -$981K
NN icon
74
NextNav
NN
$1.79B
$304K 0.14%
20,000
+7,000
+54% +$89.8K
ALLT icon
75
Allot
ALLT
$362M
$301K 0.14%
35,238
+11,000
+45% +$79.1K
1 2
3
4

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
AWM
Able Wealth Management Toms River, New Jersey $374M AUM 12.51% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return

DCF Advisers's Q2 2025 Portfolio in Review

As of Q2 2025, DCF Advisers held 92 positions worth $216M, up 3.3% from $209M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

DCF Advisers withdrew a net $12.7M in Q2 2025, closing 8 positions and reducing 20 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $462K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, DCF Advisers opened a new position in Structure Therapeutics worth $513K.

  • DCF Advisers's largest Q2 2025 buy was Structure Therapeutics: 24,750 shares worth $513K.
  • DCF Advisers added most to Evotec in Q2 2025, an estimated $1.42M increase.
  • DCF Advisers's biggest Q2 2025 reduction was SPDR Gold Trust, cutting an estimated $908K.
  • DCF Advisers fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $462K.
  • DCF Advisers's ten largest holdings make up 39% of its $216M portfolio in Q2 2025.
  • DCF Advisers opened 7 new positions and closed 8 in Q2 2025.
  • DCF Advisers's portfolio value rose 3.3% quarter-over-quarter to $216M.

Based on DCF Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.